July 11, 2019
This story was originally published on the Hematology Advisor The introduction of monoclonal antibodies and immunomodulators into earlier lines of therapy may improve progression-free survival (PFS) in patients with refractory multiple myeloma (MM), according to a study reanalyzing clinical data collected at the Winship Cancer Center at Emory University in Atlanta, Georgia. Results were published in Cancer....
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand